TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Please see the full Prescribing Information, including Medication Guide. About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...